Canopy Growth Corporation (TSX: WEED) released its Q2 FY2025 results today, revealing a mixed financial picture marked by underperformance in its Canadian cannabis segment but notable growth in international markets and premium product lines. The company’s net revenue for the quarter ended September 30, 2024, was $63 million, a 9% drop from $69.6 million in the same quarter last year.
But, the earnings report shows the firm missed analyst estimates, posting an EPS of -$1.48, falling short of the expected -$0.36. This substantial miss marks a concerning trend of ongoing losses, which has not only eroded investor confidence but raises questions about the company’s financial sustainability in the long term.
Comparing Q2 FY2025’s figures to last quarter (Q1 FY2025) shows a marginal improvement in Canopy’s gross margin, which increased by 100 basis points to 35%. However, this uptick pales in comparison to the 32% drop in Canadian adult-use cannabis sales year-over-year, down to $18.4 million from $24.1 million in Q2 FY2024. This decrease was partly due to an interruption in the supply of Wana edibles, a product line crucial to Canopy’s Canadian portfolio.
This decline in Canadian adult-use cannabis revenue was partially offset by gains in the Canadian medical cannabis segment, which saw a 16% increase to $18.7 million.
Internationally, Canopy’s cannabis segment fared better, with revenue climbing 12% to $10.1 million, up from $9 million in Q2 FY2024. This growth was driven by sales in Europe, particularly in Poland and Germany, where regulatory shifts have created new demand for cannabis products. International gross margins also improved significantly, reaching 47%, compared to 30% a year ago, as the company shifted its product mix to focus on higher-margin offerings in Europe.
In addition to international growth, Canopy’s premium vaporizer line, Storz & Bickel, delivered strong performance with a 32% revenue increase to $15.9 million, up from $12 million in Q2 FY2024. This growth was driven by strong demand in Germany, boosted by regulatory reforms, and a substantial improvement in U.S. sales, particularly as Canopy phased out older models in favor of new products.
Total operating expenses for Q2 FY2025 were $67.8 million, up sharply from $30.4 million in Q2 FY2024. This increase was driven by restructuring costs and asset impairment losses, underscoring Canopy’s ongoing struggle to streamline its operations. Selling, general, and administrative (SG&A) expenses, which totaled $41.7 million this quarter, reflect the high cost structure that has plagued Canopy’s financials for several quarters.
While management points to cost-cutting initiatives as a pathway to profitability, the steep increase in operating expenses suggests that these measures have yet to take full effect.
The company reported a $131.6 million net loss for the quarter, slightly improved from a $148.2 million net loss in the same quarter last year. Canopy attributes part of the loss to the discontinued operations and impairment costs associated with restructuring efforts.
The company’s adjusted EBITDA loss improved to $5.5 million, a 54% reduction from $11.9 million in the same period last year. Canopy’s free cash flow was an outflow of $56.4 million, down from an outflow of $67.1 million in Q2 FY2024.
The company’s cash and short-term investments did increase from $195 million at the end of Q1 FY2025 to $231 million this quarter, indicating enhanced liquidity, yet this improvement was primarily driven by new capital raised rather than organic cash flow.
On the strategic front, Canopy’s U.S. operations under Canopy USA have made significant acquisitions, including the purchase of Wana Brands and the impending acquisition of Acreage Holdings. These moves position Canopy to enter the U.S. market more aggressively, yet they also carry risks, as the U.S. federal stance on cannabis remains uncertain.
Canopy Growth last traded at $6.30 on the TSX.
Information for this briefing was found via Sedar and the sources and companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
